期刊文献+

乳腺癌干细胞激素受体与HER-2表达生物学意义的分析 被引量:5

Expression and significance of ER,PR,HER-2 in breast cancer stem cells
原文传递
导出
摘要 目的:探讨雌激素受体(ER)、孕激素受体(PR)和人类表皮生长因子受体2(HER-2)在乳腺癌干细胞(BCSCs)和其分化细胞中的表达及意义。方法:选取乳腺浸润性导管癌新鲜标本30例,采用机械分离法将乳腺癌组织块制备成单细胞悬液,通过免疫磁珠两步法从中分离出BCSCs(CD44+CD24-/low细胞)和乳腺癌分化细胞(CD24+细胞和CD44-CD24-细胞),应用免疫细胞化学Envision二步法检测两组细胞ER、PR和HER-2的表达情况。结果:BCSCs ER-表达率为83.3%(25/30),分化细胞ER-表达率为53.3%(16/30),两者差异有统计学意义,P=0.025;BCSCs PR-表达率为76.7%(23/30),分化细胞PR-表达率为23.3%(7/30),两者差异有统计学意义,P=0.000;BCSCs HER-2-表达率为83.3%(25/30),分化细胞HER-2-表达率为53.3%(16/30),两者差异有统计学意义,P=0.025;BCSCs和分化细胞表型构成不同(P=0.000),BCSCs以ER-、PR-及HER-2-表型为主,占66.7%(20/30),乳腺癌分化细胞以ER和(或)PR+、HER-2-表型为主,占43.3%(13/30)。结论:BCSCs ER、PR和HER-2均可呈现阳性或阴性表达,但以阴性表达为主,随着BCSCs的分化,其阳性表达率明显升高。BCSCs的表型以ER-、PR-及HER-2-为主,这可能是部分患者内分泌治疗失败的主要原因。 OBJECTIVE:To separate breast cancer stem cells(BCSCs) from primary human breast cancer tissue and explore the expression and significance of ER,PR, HER-2,in BCSCs. METHODS: Thirty fresh specimens of breast inva- sive ductal carcinoma were processed into single cell suspensions by mechanical separation, then BCSCs (CD44+/ CD24-/loW cells) and differentiated cells (CD24+ and CD44-/CD24- cells) were separated from them by immunomagnetic sorting. Immunocytochemical technique was employed to detect the expression of ER,PR, HER-2 in two groups. RE- SULTS.. The negative rates of ER in BCSCs were 83.3 % (25/30), in differentiated cells were 53.3 % (16/30), the differ- ences were significant (P=0. 025) ; The negative rates of PR in BCSCs were 76.7 % (23/30), in differentiated cells were 23.3%(7/30), the differences were significant (P=0. 000); The negative rates of HER-2 in BCSCs were 83. 3%(25/30) ,in differentiated cells were 53.3 % (16/30), the differences were significant (P=0. 025). The phenotype was dif- ferent too (P= 0. 000). ER--, PR-- and HER-2- were the predominant phenotypes in BCSCs, accounting for about 66.7 % (20/30). ER and/or PR+, HER-2-- were the predominant phenotype in differentiated cells, accounting for about 43.3 % (13/30). CONCLUSIONS: The expression of ER,PR and HER-2 in BCSCs can be either positive or negative, yet the majority of them are negative; With the differentiation of BCSCs,the positive rates will be higher. ER--,PR-- and HER-2-- are the predominant phenotype in breast cancer stem cells,which may relate to the failure of endocrine therapy.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2013年第12期926-929,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 山东省医药卫生科技计划(2009HZ001)
关键词 乳腺肿瘤 干细胞 免疫磁珠分选 雌激素受体 孕激素受体 人类表皮生长因子受体2 breast neoplasms stem cells immunomagnetic sorting estrogen receptor progesterone receptor human epidermalgrowth factor-2
  • 相关文献

参考文献13

  • 1Hammond ME, Hayes DF, Dowsett M, et al. American Societyof Clinical Oncology/College of American Pathologists guidelinerecommendations for immunohistochemical testing of estrogenand progesterone receptors in breast cancer [J]. J Clin Oncol,2010,28(16):2784-2795.
  • 2Wolff AC, Hammond ME, Schwartz JN, et al. American Societyof Clinical Oncology/College of American Pathologists guidelinerecommendations for human epidermal growth factor receptor 2testing in breast cancer [J], J Clin Oncol,2007,25(1) : 118-145.
  • 3Sorlie T, Tibshirani R, Parker J , et al. Repeated observation ofbreast tumor subtypes in independent gene expression data sets[J]. Proc Natl Acad Sci U S A,2003,100( 14) :8418-8423.
  • 4史亚飞,曹明智.乳腺癌干细胞的研究进展[J].中华肿瘤防治杂志,2009,16(22):1814-1817. 被引量:5
  • 5陈红秋,边建民.乳腺癌雌孕激素受体临床病理研究进展[J].广西医学,2003,25(2):220-221. 被引量:16
  • 6Dontu G, EI-Ashry D, Wicha MS. Breast cancer, stem/progeni-tor cells and the estrogen receptor [J]. Trends EndocrinolMetab,2004,15(5) :193-197.
  • 7Gadalla SE, Alexandraki A, Lindstrom MS, et al. Uncoupling ofthe ERa regulated morphological phenotype from the cancer stemcell phenotype in human breast cancer cell lines [J]. BiochemBiophys Res Commun,2011,405(4) :581-587.
  • 8姚宇锋,唐金海,秦建伟.乳腺癌原发灶和复发灶组织HR和C-erbB-2及P-gp差异性表达的研究[J].中华肿瘤防治杂志,2012,19(3):209-211. 被引量:7
  • 9Roesler R,Cornelio DB. Abujamra AL,et al. HER-2 as a cancerstem-cell target [J]. Lancet Oncol,2010,11(3) :225-226.
  • 10Korkaya H, Paulson A, Iovino F et al. HER-2 regulates themammary stem/progenitor cell population driving tumorigenesisand invasion [J]. Oncogene,2008,27(47) :6120-6130.

二级参考文献46

  • 1宋旭东,王献华,张素华,郑素芹,李琪佳,向巨才.158例乳腺癌雌孕激素受体表达分析[J].华北煤炭医学院学报,1999,1(6):503-504. 被引量:1
  • 2王崇宇,杨苏敏,原学斌,刘苗生,张淑玲.乳腺癌雌激素与孕激素受体的表达及其临床意义[J].长治医学院学报,1995,9(3):191-193. 被引量:1
  • 3吴祥德 董守义.乳腺疾病诊治:第1版[M].北京:人民卫生出版社,1996.326-327.
  • 4Bonnet D, Dick J E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J]. Nat Med,1997,3(7):730-737.
  • 5Hanahan D, Weinberg R A. The hallmarks of cancer[J]. Cell, 2000,100(1):57-70.
  • 6Patrawala L, Calhoun T, Schneider Broussard R, et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2^+ and ABCG2^- cancer cells are similarly tumorigenic[J]. Cancer Res, 2005. 65(11): 6207-6219.
  • 7Kondo T, Setoguchi T, TagaT. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line[J]. Proc Natl Acad Sci USA, 2001, 101(3): 781-786.
  • 8Al Hajj M. Wicha M S, Benito-Hernandez A. et al. Prospeclive identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA, 2003. 100(7): 3983-3988.
  • 9Fillmore C M, Kuperwasser C. Human breast cancer cell lines contain stem like ceils that self renew, give rise to phenotypically diverse progeny and survive chemotherapy[J]. Breast Cancer Research. 2008, 10(2): 25.
  • 10Hess D A. Wirthlin L, Craft T P, et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long term reconstituting human hematopoietic stem cells[J]. Blood. 2006,107(5):2162-2169.

共引文献25

同被引文献63

  • 1阎子海,肖永红,张文杰,韩向午.心理因素与女性乳腺癌关系的Meta分析[J].中国公共卫生,2006,22(6):748-748. 被引量:16
  • 2黎惠娟.健康教育对乳腺癌术后患者生存质量的影响[J].中国实用护理杂志(下旬版),2006,22(6):53-54. 被引量:4
  • 3林绵辉,吴芳,邓小戈,胡春宏,肖涛,蒋少艾.曲妥珠单抗治疗HER2阳性早期乳腺癌患者预后的Meta分析[J].循证医学,2006,6(6):352-356. 被引量:3
  • 4Landen CN Jr,Birrer MJ,Sood AK. Early events in Ihe patho- genesis of epithelial ovarian cancer[J]. J C lin Oncol, 2008,26(6):995-1005.
  • 5Kurman RJ,Shih IeM. The origin and pathogenesis of epithelial ovarian eancer~ a proposed unifying theory [J]. Am J Surg Pathol,2010,34(2) :433.
  • 6Li J,Fadare O, Xiang L, et al. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis[J]. J Hematol Oncol, 2012,5:8.
  • 7Wiegand KC,Shah SP,Al-Agha OM,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas[J]. N Engl J Med, 2010,363 (16) : 1532-1543.
  • 8Raynaud CM, Mercier O, Commo F, et al. Telomere length, telo- meric proteins and DNA damage repair proteins are differentially expressed between primary lung tumors and their adrenal metas- tases[J]. Lung Cancer,2009,65(2) : 144-149.
  • 9Gottwald L,Kubiak R,Pasz-Walczak G. et al. The value of pro- gesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer[J]. Ginekolpol,2013,84(2) :95-101.
  • 10Young RH,Scully RE. Metastetic tumor of the ovary//Kurman RJ. Blumstein's gynecologic pathology of the femal genital tract [M] .5th ed. New York:Springer,2002:1063 -1101.

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部